Role of 18F-FDG PET/CT in the diagnosis and management of multiple myeloma and other plasma cell disorders: a consensus statement by the International Myeloma Working Group

Anti-CD19 CAR T cells with high-dose melphalan and autologous stem cell transplantation for refractory multiple myeloma

“…Cross-sectional imaging showed multiple extramedullary plasmacytomas in both subjects as the only clinically significant disease manifestations (retroperitoneal and gluteal plasmacytomas in subject 1, pleural plasmacytomas in subject 5). On positron emission tomography, the extramedullary plasmacytomas in both subjects 1 and 5 did not exhibit fluorodeoxyglucose uptake above background levels, suggesting indolent disease; this is unusual for extramedullary multiple myeloma, which is usually fluorodeoxyglucose-avid by this modality (40). Though multiple myeloma in subject 5 eventually developed a more aggressive and treatment-refractory clinical course, multiple myeloma of subject 1 remained indolent and uncharacteristically responsive to subsequent therapy.…”

Prognostic significance of bone marrow abnormalities in the appendicular skeleton of patients with multiple myeloma

“…Magnetic resonance imaging (MRI) and PET/CT are considered as good alternatives for the detection of lytic bone lesions and bone marrow lesions. 19,20 However, both imaging modalities are expensive and time-consuming when compared with whole-body MDCT with coverage of extra spine being typically limited in MRI. Furthermore, focal medullary lesions without lytic bone change in the AS may not be correctly evaluated as myelomatous lesions in PET/CT due to low fluorodeoxyglucose uptake.…”

Incidental Discovery of Multiorgan Extramedullary Plasmacytomas in the Setting of Newly Diagnosed Multiple Myeloma and Delayed Hemolytic Transfusion Reaction

“…Once the presence of EMPs is established, after the initial PET-CT, it should be repeated to assess response 2 cycles after treatment and at treatment completion to ensure complete remission [2]. It is noteworthy to add that the International Myeloma Working Group recently published a consensus statement recommending the use of PET-CT in the initial workup of all newly diagnosed patients with multiple myeloma, as well as patients with refractory or relapsed myeloma, given its high sensitivity in detecting extramedullary disease as well as its superiority in determining metabolically active disease and early determination of treatment response [11]. …”